Inotuzumab ozogamicin (INO) is an anti-CD22 antibody-drug conjugate that was first evaluated in B-cell lymphomas but was subsequently shown to be highly effective in acute lymphoblastic leukemia (ALL). INO improved response rates and survival in a randomized study in adults with relapsed/refractory B-cell ALL, leading to its regulatory approval in the United States in 2017. While the formal approval for INO is as monotherapy in relapsed/refractory ALL, subsequent studies with INO administered in combination with chemotherapy and/or blinatumomab both in the frontline and salvage settings have yielded promising results. In this review, we discuss the clinical development of INO in ALL, highlighting lessons learned from the initial clinical trials of INO, as well as the many ongoing studies that are seeking to expand the role of INO in ALL.

中文翻译：

---

伊诺珠单抗奥佐米星治疗成人急性淋巴细胞白血病：过去的进展、当前的研究和未来的方向

Inotuzumab ozogamicin (INO) 是一种抗 CD22 抗体药物偶联物，首先在 B 细胞淋巴瘤中进行评估，但随后被证明对急性淋巴细胞白血病 (ALL) 非常有效。在一项针对成人复发/难治性 B 细胞 ALL 的随机研究中，INO 提高了缓解率和生存率，并于 2017 年在美国获得监管批准。虽然 INO 的正式批准是作为复发/难治性 ALL 的单一疗法，但后续研究INO 与化疗和/或 blinatumomab 联合用药在前线和抢救环境中都取得了有希望的结果。在这篇综述中，我们讨论了 INO 在 ALL 中的临床开发，重点介绍了 INO 初始临床试验的经验教训，以及许多正在进行的旨在扩大 INO 在 ALL 中作用的研究。